NASDAQ · OTLK
Healthcare · Biotechnology
$0.49
Up+$0.03 (+5.48%)
Updated Oct 20, 2026, 10:42 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OTLK
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
OTLK closed at $0.49 after 21 trading sessions, down 28.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $0.4903 | $0.5217 | $0.4809 | $0.493 | 2.61M |
| Oct 16, 2026 | $0.52 | $0.5326 | $0.485 | $0.4882 | 3.12M |
| Oct 15, 2026 | $0.4881 | $0.5099 | $0.4379 | $0.50 | 5.35M |
| Oct 14, 2026 | $0.5571 | $0.5651 | $0.47 | $0.4702 | 9.64M |
| Oct 13, 2026 | $0.5788 | $0.5812 | $0.551 | $0.5638 | 3.25M |
| Oct 12, 2026 | $0.599 | $0.60 | $0.57 | $0.5851 | 2.31M |
| Oct 9, 2026 | $0.5675 | $0.605 | $0.5557 | $0.5989 | 3.69M |
| Oct 8, 2026 | $0.58 | $0.5898 | $0.5506 | $0.564 | 4M |
| Oct 7, 2026 | $0.6023 | $0.6066 | $0.58 | $0.59 | 4.24M |
| Oct 6, 2026 | $0.60 | $0.62 | $0.572 | $0.572 | 3.16M |
| Oct 5, 2026 | $0.60 | $0.6101 | $0.58 | $0.5955 | 4.69M |
| Oct 2, 2026 | $0.59 | $0.6067 | $0.5723 | $0.593 | 5.62M |
| Oct 1, 2026 | $0.58 | $0.5904 | $0.5314 | $0.575 | 7.07M |
| Sep 30, 2026 | $0.6257 | $0.6347 | $0.5729 | $0.5735 | 9.01M |
| Sep 29, 2026 | $0.63 | $0.6359 | $0.6118 | $0.6257 | 4.58M |
| Sep 28, 2026 | $0.63 | $0.6379 | $0.6005 | $0.6211 | 6.1M |
| Sep 25, 2026 | $0.6551 | $0.6705 | $0.636 | $0.6395 | 2.94M |
| Sep 24, 2026 | $0.66 | $0.6798 | $0.6411 | $0.6558 | 2.78M |
| Sep 23, 2026 | $0.7045 | $0.7045 | $0.6617 | $0.6617 | 2.93M |
| Sep 22, 2026 | $0.6863 | $0.7137 | $0.6766 | $0.6962 | 2.86M |
| Sep 21, 2026 | $0.6853 | $0.695 | $0.6527 | $0.6863 | 2.88M |
The latest Smart Investors Daily articles mentioning OTLK.
Company
Market Activity
Research & News
OTLK research
Company profile and research snapshot.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Ascendiant Capital | Buy | — |
| Aug 14, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 11, 2026 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A
Benzinga · Feb 19, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service
Benzinga · Feb 18, 2026
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $0.5 price target.
Benzinga · Feb 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OTLK.
